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Abstract
Background: Every year, research specimens are shipped from one institution to another as well as across national
boundaries. A significant proportion of specimens move from poor to rich countries. Concerns are always raised on
the future usage of the stored specimens shipped to research insitutions from developing countries. Creating
awareness of the processes is required in all sectors involved in biomedical research. To maintain fairness and
respect in sharing biomedical specimens and reserch products requires safeguarding by Ethics Review Committees
in both provider and recepient institutions. Training in basic ethical principles in research is required to all sectors
involved in biomedical research so as to level up the research playing field.
Discussion: By agreeing to provide specimens, individuals and communities from whom samples are collected
would have placed their trust and all ensuing up-keep of the specimens to the researchers. In most collaborative
set-up, laid down material transfer agreements are negotiated and signed before the shipment of specimens.
Researchers, research ethics committees (RECs) and institutions in the countries of origin are supposed to serve as
overseers of the specimens. There is need to advocate for honesty in sample handling and sharing, and also need
to oversee any written commitments by researchers, RECs and institutions at source as well as in recipient
institution. Commitments from source RECs and Institutional Review Boards (IRBs) and in the receiving institution
on overseeing the future usage of stored specimens are required; including the ultimate confirmation abiding by
the agreement. Training in ethical issues pertaining to sample handling and biomedical research in general is
essential at all levels of academic pursuit. While sharing of biological specimens and research data demands
honesty and oversight by ethical regulatory agents from both institutions in developing country and recepient
institutions in developed countries.
Concluding summary: Archiving of biological specimens requires reconsideration for the future of biomedical
findings and scientific break-throughs. Biomedical ethical regulations still need to established clear viable
regulations that have vision for the future of science through shared and archived samples. This discussion covers
and proposes essential points that need to be considered in view of future generations and scientific break-
throughs. The discussion is based on the experience of working in resource-limited settings, the local regulatory
laws and the need to refine research regulations governing sharing and storage of specimens for the future of
science.
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Background
Conditions and the proper working of International Ethics
Committees (IECs), National Ethics Committees (NECs)
and similar bodies may differ in size, composition, working
methods and mandates, but the impact of the ethics com-
mittees on public debates and legislation depend on the
knowledge, wisdom, commitment and willingness to work
of the members. The goals of national & international
ethics committees include identifying important ethical
issues, facilitating the ethical debates in their countries by
providing relevant background material and advancing
sound reasons of recommendations on what to do and
what to avoid in difficulty and complex issues. NECs base
their conclusions on a broad value judgment combined
with relevant information not only on just scientific infor-
mation, but also on people’s attitudes, existing regulations,
societal trends, economic conditions and other con-
sequences [1-4]. Since bioethics is not a subject that is
taught in many universities around the world, there is
need to promote, disseminate and elaborate on the
bioethical principles laid down in all regulatory documents
like Council for International Organization of Medical
Sciences, Belmont report, Nuffield Council on Bioethics,
World Medical Associations, etc [1-5]. Research is carried
out in a scarce-resource population, mainly through public
institutions and links with researchers. This is a very
important issue because it has an impact on informed con-
sent as well as on benefit sharing and the social relevance
of the research conducted [5].
Research on genetics and the storage of body tissue
(biobanks) have increased the work and challenges faced
by REC or IRBs. NECs regulate the functioning of RECs
in the country and to develop or strengthen the legal fra-
mework governing research with human participants
[5,6]. Generally, most resource-constrained areas/com-
munities have banned the export of biological materials
until a legal framework is established [7]. While this step
is important for the health authorities in several coun-
tries, this poses in turn great challenges to those whose
research requires the export of samples to other coun-
tries. The researcher fraternity is somehow disturbed
with reports indicating that some IRBs are rejecting
research where the storing of coded samples form an
integral part of the study [8]. Such protocols were
rejected because the IRBs were concerned that the parti-
cipant protection was not guaranteed and also due to
likely uncontrolled use of the biological materials at the
recipient institution. The concerns were justified as the
participants that provided the samples may have not fully
understood the range of tests that can be done on their
samples. While researchers are expected to behave in
ethical manner, it cannot be ruled out of the extent the
researchers can go with all the samples at their disposal
[7]. Based on the type and magnitude of some research
being approved and conducted in poor and developing
communities, it may be highly possible that some
researchers conduct seemingly minor or simple harmless
studies just to get access to some samples for storage,
export or use in unethical or unapproved research. Spec-
ulation cannot be avoided in which some researchers sell
samples to laboratories unknown to IRBs/RECs. Given
the magnitude of the information that scientists can
derive from stored specimens. As such, RECs/IRBs need
to be concerned and wary when issuing out approvals,
especially to a collaborative group with institutions scat-
tered all over the world.
Most developing countries would need to conduct
high-tech scientific research but due to poverty and
unavailability of some basic equipment, limitation exists.
While institutions in developed countries that show
intent to do research in developing countries offer a
good solution, challenges still exits on the modalities.
This is so often because they meet the cost of the study
and provide expertise. However, specimens are usually
shipped out of developing country under the pretext of
lacking facilities for storage and equipment to run
advanced analysis. Researchers in developed countries
benefit far much more from most types of collaboration
that they are often unwilling to invest in strengthening
capacity of the weaker institution in the host country
[6,9]. A trend has appeared in the research arena almost
like modern day of colonization through sharing regions
or areas of resource poor communities. Moreover, some
research proposal and protocols are submitted to IRBs/
RECs without local investigators until advised and
pointed out by the reviewing teams [9,10]. Very often it
is likely that due to pressure on academic institutions to
conduct research and publish their findings as a require-
ment for promotion, has tempted some researchers to
compromise on ethical standards, resulting in great chal-
lenges posed by biobanking and the export of samples.
However, regulations should be made flexible to accom-
modate rapid scientific advances [8,11]. Sometimes strin-
gent measures may be required to protect these samples,
but such measures may not be good for the future of
science, hence paving way for the need to balance during
protocol review process [12,13], and taking cognizance of
the need to be able to track the evolution of the diverse
disease conditions for the sake of the future discoveries
or unraveling of current disease challenges [8,13].
Biomedical research has led to significant improvement
and advancement in medical field and more is still needed
to further improve preventive, diagnostic and therapeutic
approach including proper ways to tackle emerging health
related challenges [11,14-16]. In this regard, the research
participant need to be protected as well as setting accepta-
ble regulations in the research arena involving researchers,
coworkers and collaboration, especially putting in place
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more emphasis on participant and the researcher in
resource-limited areas. There are several ethical and prac-
tical challenges faced by researchers that normally go
unresolved, especially affecting researchers and partici-
pants in developing countries. The discussion involves
ethical and practical challenges encountered in resource-
constrained settings, and explores some possible ways to
overcome the challenges. Further, giving analyses of the
challenges surrounding sharing products of the research
collaboration. Hoping that the discussed issues will go a
long way sensitizing investigators and the related stake-
holders on the need to operate within the research ethical
framework for both the participants and the researchers
and further assist in setting up relevant ethical guidelines
or legal frameworks.
Currently, Africa is faced with several diseases that are
playing havoc on socioeconomic development, giving an
environment highly fertile and conducive for biomedical
research on its inhabitants [11,15,16], and also likely
opportunity for collaboration that can exploit the avail-
able experts, researchers and their resources. Africa still
has massive deficit in health research capacity in num-
bers and competencies, underdeveloped research institu-
tions compounded by poor networking opportunities for
collaboration. Collaborative research has been on the
increase; there are now an increased number of institu-
tions that enable research scientists from developed
countries to undertake research [9,10,14,17]. In turn
there has been an upsurge of institutional and govern-
mental agents that purportedly support research but have
come up with stringent regulations to monitor flow of
data and samples between collaboration. In certain coun-
tries the governmental department of customs and exer-
cise has been included in monitoring the flow of this
essential research commodity. All this indicating that the
research landscape across Africa has changed consider-
ably where there are now locally owned and led research
institutions [9]. These have institutional research ethics
committees that require standardization in as far
as operation is concerned in sample sharing during
collaboration.
At times non-governmental players based in both devel-
oped and developing countries that are involved in commu-
nity based activities have assisted in advocacy, mobilizing
funds to enable training in an attempt towards increased
attention to good collaboration and sharing the products of
research [9]. Some are engaged in capacity strengthening of
health research institutions and researchers in developing
countries. Strengthening of research capacity and the inclu-
sion of training in universities and colleges curricula may
go a long way in empowering the limited resources research
for decision making and demanding equal collaboration
and sharing of research products. Although there has been
considerable advancement in resolving the 10/90 gap,
particularly with respect to communicable diseases, the gap
maybe widening due to the rapid technological advance-
ment in developed countries and the ever increasing epide-
miological diseases of infectious and non communicable
nature [11].
Some institutions in resource-limited areas have strong
leadership and almost a universal collaboration policy,
even though this appears as the aftermath of the scram-
ble for study sites in developing countries that resulted in
research institutions and some universities located
in developed countries sharing the research sites situated
in resource-limited areas. A considerable investment has
been achieved in setting up IRBs and NEC for regulation
purposes and to protect study participants [18]. Much
efforts should be made to link various researchers and
research endeavours by establishing collaborative multi-
disciplinary teams, links and consortia that should be
able to address research problem holistically [9]. There is
also the need for increased numbers of researchers and
research institutions capable of creating research agenda
and operational guidelines on sharing specimens and
research products, increased collaboration and adapting
research findings into policy [14]. Qualified researchers
and managers should be able to mentor and train juniors,
develop and sustain a fruitful research culture, manage
risk, be accountable and trustworthy. Establishing strong
collaboration with northern partners and sharing
unwinding of good collaboration policies with their
southern partners in an effort to make uniform policies.
Most NECs, IRBs and ERCs recently established over the
last two decades have already contributed immensely to
ongoing clinical and field trials and also to the future
ones and even to the improvement of health research sys-
tems, while more should be invested in sharing the pro-
ducts of research.
Such set-ups have made the research fraternity realize
the benefits of research regulations, bringing in sanity to
mostly a deceptive environment in collaboration. While in
the process of contributing to resolving health challenges,
the research jungle seems to ultimately get tamed. How-
ever, not much has been realized along specimen sharing
between resource-limited areas and highly financed insti-
tutions in developed countries. The challenges ushers in
the need to address at an early stage on how southern
research partners and their communities would derive
benefits from such research and participation. Also taking
into consideration the future of science from the viewpoint
on the need for biobanks. There is also need for proper
review of the research protocol and ethical issues, the
need for training researchers and associated personnel,
mentorship, develop institutional leadership personnel
with a wide vision and able to play a major role as mem-
bers of committees to review study designs and provide
clinical and field project oversight. In particular, where
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some of the neglected diseases that need health research
attention are endemic, research is conducted only in
remote areas, which are difficulty to reach and rarely are
closely monitored by the in-country regulatory authorities
due to resource limitation for making follow-up.
The ethics on research collaboration
Several research programmes have exhibited traces of
deception to the vulnerable collaborative researchers or/
and participant in resource-limited areas. Exploitation of
the vulnerable researcher or participant is normally man-
ifested in coercive or deceptive research implementation
strategies. Most of these exploitative activities go unno-
ticed where research oversight is not well established.
The remedy for exploitation in research lies in thor-
oughly and adequately well-informed research participant
[18,19], combined with procedures that respect the cardi-
nal principles of autonomy, beneficence, non-maleficence
and justice [1-4]. A high burden of disease, combined
with desperate poverty and ignorance make people in
resource-limited settings highly vulnerable to exploitation
[14]. Populations of resource-constrained settings are
highly vulnerable in biomedical research, while research
in such settings in justifiable to solve the urgent health
challenges, care must be taken to avoid harming, exploit-
ing or otherwise treating research participants in unethi-
cally acceptable ways [7,9,17].
Shared specimens play a very important role in the
future of sciences. Imagine the discovery of HIV from
the archived samples that later provided all the clues after
the patients who provided the samples and clinical history
had long deceased. The archived samples contributed to
unraveling the mysterious infection that had devastated
certain sectors of the world population to be discovered
[20-22]. Places all over the world have unique health chal-
lenges that call for biobanking, necessary for continuing
investigation. The ethical issues surrounding such com-
modity in research may demand sculpturing operational
codes that should bring in rational sharing of such impor-
tant research study materials. However, due to limited
resources in developing areas that lack capacity to plan
ahead and fail to establish storage facilities, a greater num-
ber of specimens are shipped to developed countries with
well established and resourced research facilities and
experts [6,12]. However, are these specimen ethically and
legally collected with the full knowledge in the collabora-
tive research and by the regulatory authorities?
Most of the genetic epidemiological studies may be based
on data of the diseases or traits derived from families,
ethnic groups, communities or populations. To understand
such trends and traits involve use of blood samples for
DNA extraction that may generate databases with genetic
phenotypic, clinical and socio demographic data [13].
Although participants may give informed consent in their
own capacity, their involvement in such studies could affect
communities, ethnic groups or the populations in diverse
ways. In the case of international collaborative studies that
involve sharing of specimen or simple shipping samples,
usually from South to North or to high technology labora-
tories. Some materials may either be collected prospectively
or the materials extracted from stored samples. The use of
stored human samples is a challenge that has sparked
debate globally [6,20]. The stored samples could have accu-
mulated from routine diagnostic and treatment activities of
health institutions or from heath research conducted over
several years back. Due to the ethical, legal and socio-
economic issues surrounding such product of research
activities in resource limited settings, there is need to come
up with progressive legislative and regulatory framework
aimed at addressing such issues. Currently, most interna-
tional collaborative research projects focusing on diseases
of the poor collect specimens from developing countries
and calls for the development of necessary framework for
research using archived samples. A simple interrelationship
is shown in Figure 1, portraying stages that can be
strengthened to rationalize ethically sharing of specimens.
However, some developing countries have now come up
with repressive regulations that will do injustice to the
future of science.
Although some tests may not be available or affordable
to the majority of populations in developing countries,
there is no justification in using such pretext to shipping
biological materials to highly developed countries for the
sake of future access to these valuable materials. Some
research institutions in developed countries have been
shipping such valuable materials over a very long period
without revisiting to solve the source of the identified
weaknesses, thereby showing insincerity in their activities
and excuses. Sometimes samples may be collected pro-
spectively, ideally after obtaining ethical approval from
relevant Ethics Review Committees and informed con-
sent from individuals. It is normally important for
researchers to ensure that the informed consent captures
all issues that are concerned to the participants and their
communities [6,12,18]. All such concerns need to be
addressed upfront with the target community, in advance
of sample targeted for shipping. Note that prospective
collection of samples for archiving requires dealing with
pertinent ethical and practical issues upfront and extreme
openness. Some archived samples from health institu-
tions may be appropriate but again there are some legal
ethical issues to be addressed early. Archived samples
from previous research projects are a common feature of
teaching hospitals where some clinicians undertake
research as well as treatment management. There are
also samples stored in national and private commercial
biobanks, even though rare in resource constrained areas.
Regardless of the source of samples, general personal
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identifiers may be delinked such as participant names,
address, birth, hospital admission number or national
registration number but still the samples may be linked
with community, village, or country [19], hence clear
ethical approval is necessary.
Ethical issues surrounding sharing of samples
Researchers have the obligation to design protocols that
discloses all the critical information about the study, giving
the prospective participant to understand the potential
risks, potential benefits [19]. While voluntariness in the
informed consent may be compromised in as far as archiv-
ing of some samples from resource limited settings, it is
difficulty to justify use of samples collected long back for a
current investigation [8,13]. This has impact on the pro-
gress of science, making use of any available material to
understand the challenges that face human health in
future. Consent for stored samples for future research
really circumvents such obstacles in which the use of such
samples is not diseases specific but is essentially important
to unravel the problem from health challenges. Sometimes
researchers ask for consent to use collected samples in
yet to be designed experiments. Giving an open-ended
consent is analogous to giving a blank signed cheque to
researchers [20]. There is need to sensitize Ethics Review
Committees in developing countries to deal with the
informed consent for future specimen use. Commonly,
scarcity of information exists in developing countries
on the best practice to address such issues. Sharing of
specimens and future use require in-depth consideration
and analysis by the responsible authorities during review
of protocols, consent forms as well as relevant regulatory
frameworks that play a part in the approval of proposals.
Due to the nature of certain research studies, community
engagement may help to ensure that there is awareness
about the research at community level and not just at indi-
vidual level. The community from which the individual
sample is collected should know the intended archiving
for non-specific investigation in future [13,18,20]. Nor-
mally, the ordinary community participant is sidelined
while the research ethics issue is addressed along some
research activities for academic purposes.
The shared or archived specimens have the potential to
generate new knowledge that may not have direct benefits
to the time of the sample collection. Whereas, some
research activities such as clinical trials may benefit the
study participants directly, archived specimen tends to
generate knowledge, which may not lead to some inter-
vention immediately. In addition, although the research
outcome of the future endeavor using stored specimens
could generate generalizable knowledge that could benefit
mankind, but not direct benefits are realized by the
researchers involved in the initial work where samples
were collected [20]. The benefits are generally realized by
the stronger group (Figure 1) in the developed country
where the archiving is done and the driving sponsor of
such endeavor who in most cases may be pharmaceutical
Figure 1 Showing the flow of data and specimen from resource limited settings to resourced and developed centres. The top part
showing resourced centres may even create further specimen exchange that does not involve the researchers and the participating institution
from developing countries. National ethics committees in resource limited areas need to establish links with corresponding national and
institutional ethics committees in countries where samples are shipped.
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company with commercial benefits, while the donor may
not even access the commercial products derived from
research testing on their samples [14].
Collaboration and sharing of research products
Another contention in sharing of samples and data
between researchers and their institutions is openness dur-
ing future use of stored specimens or data. Epidemiologi-
cal studies focusing on diseases of the poor countries
bring together collaboration between researchers from
North in collaboration with those in South; or sometimes
some consortia or many institutions are formed so as to
achieve large sample sizes quickly within reasonable time.
The collaborators from developed countries usually are
the leaders of the research grants and may possess the
technology, and end up in full control of all the collected
data at the end of a given study. The benefits are only dis-
cernible during the active study while later, the researchers
from resource-limited areas are not included as part of the
studies on the archived specimens (Figure 1). Such occur-
rences reveal a lack of capacity in most developing coun-
tries to store large quantities of samples on a long-term
basis and for future use. Most developing countries do not
have the capacity to store large quantities of samples on a
long-term basis and for future investigative activities
hence samples are shipped to collaborative centres in
developing countries for storage.
The developing countries or resource-limited areas play
the role of sample collection ground, even though the ben-
efits derived from research may eventually spread to all
parts of the world, only would continuous benefits be rea-
lized if such areas were capable of sample storage and ana-
lysis. The challenges require immediate addressing right
from drawing up the protocols on sample sharing and the
research outcome of the data (Figure 1). The informed
consent should explicitly explain all pertinent issues early
in the study, should explain the rationale behind the need
to store samples for future use. Another aspect of mini-
mizing conflict and deception is to have well-trained ethics
review committees capable of critically reviewing the perti-
nent issues during review process. After approval, the
communities need to be empowered to be able to monitor
the research with the monitoring extending beyond the
life span of the approved project. The ERCs should be vigi-
lant while analyzing protocols with indication for future
research that may inappropriately be based on stored sam-
ples and ethical approval given for previous investigations.
Resource constrained areas need to empower national reg-
ulatory authorities and set up regulation that are particu-
larly relevant to the developing world perspective and may
not address some of the issues prevailing in the settings.
Very often there is need to establish material transfer
agreement that may regulate and make it known of the
intention for archived samples.
Every research protocol that would involve sharing
samples require establishing of these regulations
upfront, stating all details as the number of the samples
to be transferred, the purpose for which the samples
should be used, the research institution permitted to use
the samples, whether or not they may be stored for pos-
sible future research and the details of such future
research. The clarity should include whether the perso-
nal identifiers should be removed before transfer. Com-
munities need to be engaged right from start and all
details revealed of the intention. There are various mod-
els of community engagement and researchers have to
find out models that would be acceptable in the particu-
lar communities where the study is to be conducted.
This has to be emphasized that community engagement
should be well planned upfront, included in the budget
and in the project timeframe just like other project
activities.
Further, members making up regulatory authorities
require continuous training to understand the benefits
in shared samples. Regulations of studies and protocols
require to appreciate the knowledge that can be gener-
ated from stored specimen including pre-symptomatic
detection of some predisposition condition to certain
diseases that may required archiving of specimen where
such facilities exists for future testing. The regulatory
authorities probably would need to incorporate technol-
ogy transfer and capacity building to go along with
transfer of samples and sharing of specimens. Wherever
possible, efforts should be made to transfer relevant mod-
ern technology from developed countries to resource
constrained areas to enable full utilization of all research
materials without resort to shipping samples, where close
monitoring may be lacking. Capacity building in terms of
human resources and infrastructure development in spe-
cialized fields would enable sustainable utilization of the
available data and resources without dispatching to other
regions. All sectors of the country need to play their own
role for the success of self-reliance. It is critical for devel-
oping countries to have research agendas that address
local challenges from diseases and to have future vision
to solve current medical problems. National ethics com-
mittees in resource limited areas need to establish links
with corresponding national and institutional ethics com-
mittees in countries where samples are shipped, as a way
to safe guard proper use of the shared samples.
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